Structure Therapeutics
GPCR
Market cap $1.09B

19.01 USD

+0.11

0.58%

At close Jul 11, 4:00 PM EDT

After hours

19.71

+0.70

3.68%

1 day

0.58%

5 days

-6.81%

1 month

-16.33%

3 months

19.56%

6 months

-24.44%

Year to date

-32.56%

1 year

-55.54%

5 years

-26.88%

10 years

-26.88%

About: Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Employees: 183

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

6% more call options, than puts

Call options by funds: $12.4M | Put options by funds: $11.7M

8% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 50

2.8% less ownership

Funds ownership: 35.31% [Q4 2024] → 32.51% (-2.8%) [Q1 2025]

7% less funds holding

Funds holding: 163 [Q4 2024] → 151 (-12) [Q1 2025]

31% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 35

40% less capital invested

Capital invested by funds: $1.65B [Q4 2024] → $981M (-$665M) [Q1 2025]

80% less funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 1 (-4) [Q1 2025]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$60

216%

upside

Avg. target

$72

280%

upside

High target

$89

368%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Cantor Fitzgerald Prakhar Agrawal	242%upside $65	Overweight Reiterated	23 Jun 2025
JMP Securities Jonathan Wolleben	368%upside $89	Market Outperform Reiterated	23 Jun 2025
HC Wainwright & Co. Andrew Fein	295%upside $75	Buy Maintained	12 May 2025
Citigroup Samantha Semenkow	216%upside $60	Buy Initiated	2 May 2025

See Analyst Rankings

Financial journalist opinion

CNBC Television

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Zacks Investment Research

NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback

Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.

NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

Viking Therapeutics, Inc. VKTX, Eli Lilly And Co LLY and Novo Nordisk A/S NVO stocks are trading higher on Monday.

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

Biotech stocks have been hit hard. Why they're a great value now.

Biotech is one of the U.S. stock market's most unloved sectors. But several indicators suggest that a bottom in sentiment could be near, and that's normally a good time to buy.

Biotech stocks have been hit hard. Why they're a great value now.

CNBC Television

Structure Therapeutics CEO on latest GLP-1 developments

Ray Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk advancements in weight loss drugs and the development of a GLP-1 pill.

Structure Therapeutics CEO on latest GLP-1 developments

CNBC Television

Final Trade: PYPL, UBER, NKE, GPCR

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Final Trade: PYPL, UBER, NKE, GPCR

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, aleniglipron, an oral GLP-1R agonist, shows potential in obesity treatment with significant Phase 2 data expected in Q4 2025. Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer a competitive edge.

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

The Motley Fool

Why Structure Therapeutics Stock Was Stumbling This Week

The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (GPCR 0.16%), was a victim of a general rout in the segment.

Why Structure Therapeutics Stock Was Stumbling This Week

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March.

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

See News Rankings

Charts implemented using Lightweight Charts™